| Bioactivity | TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells[1]. | ||||||||||||
| Invitro | TZ9 (Rad6B SMI #9) (0.5-100 µM; 72 h) inhibits MDA-MB-231 cell proliferation and migration[1].TZ9 (0.1-5 µM; 24-72 h) delays cell-cycle progression in MDA-MB-231 cells[1].TZ9 (5 µM; 8-48 h) induces apoptosis in MDA-MB-231 cells[1].TZ9 (0.5, 1, 2.5, 5 µM; 24 h) inhibits H2A ubiquitination and downregulates levels of PCNA and β-catenin protein in MDA-MB-231 cells[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | TZ9 | ||||||||||||
| CAS | 1002789-86-7 | ||||||||||||
| Formula | C17H14N6O4 | ||||||||||||
| Molar Mass | 366.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12(4):373-83. |